General Information of Drug (ID: DMXLBCQ)

Drug Name
Sodium phenylbutyrate
Synonyms
Ammonaps; Buphenyl; EL-532; Sodium 4-phenylbutyrate; Sodium phenylbutyrate, Elan; Sodium phenylbutyrate, Medicis; Sodium phenylbutyrate, Ucyclyd; VP-101; Sodium 4-phenylbutyrate, Elan; Sodium 4-phenylbutyrate, Ucyclyd; Sodium phenylbutyrate (cancer), MacroChem/Access; Sodium phenylbutyrate (cancer), Virium/ Somanta; Sodium phenylbutyrate (cancer), Virium/Access Pharmaceuticals; Sodium 4-phenyibutyrate (cancer), MacroChem/Access; Sodium 4-phenylbutyrate (cancer), Virium/ Somanta; Sodium 4-phenylbutyrate (cancer), Virium/Access Pharmaceuticals
Indication
Disease Entry ICD 11 Status REF
Spinal muscular atrophy 8B61 Approved [1]
Spinal muscular atrophy, type II N.A. Approved [2]
Urea cycle disorder 5C50.A Approved [2]
Citrullinemia N.A. Investigative [2]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski):
0
Molecular Weight 186.18
Logarithm of the Partition Coefficient Not Available
Rotatable Bond Count 4
Hydrogen Bond Donor Count 0
Hydrogen Bond Acceptor Count 2
Chemical Identifiers
Formula
C10H11NaO2
IUPAC Name
sodium;4-phenylbutanoate
Canonical SMILES
C1=CC=C(C=C1)CCCC(=O)[O-].[Na+]
InChI
InChI=1S/C10H12O2.Na/c11-10(12)8-4-7-9-5-2-1-3-6-9;/h1-3,5-6H,4,7-8H2,(H,11,12);/q;+1/p-1
InChIKey
VPZRWNZGLKXFOE-UHFFFAOYSA-M
Cross-matching ID
PubChem CID
5258
ChEBI ID
CHEBI:75316
CAS Number
1716-12-7
TTD ID
D0P2GK
ACDINA ID
D00633
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histone deacetylase (HDAC) TTBH0VX NOUNIPROTAC Inhibitor [3]
Protein kinase C alpha (PRKCA) TTFJ8Q1 KPCA_HUMAN Modulator [4]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
116 kDa U5 small nuclear ribonucleoprotein component (EFTUD2) OT3X7QG2 U5S1_HUMAN Gene/Protein Processing [5]
Actin, aortic smooth muscle (ACTA2) OTEDLG8E ACTA_HUMAN Gene/Protein Processing [6]
Activator of 90 kDa heat shock protein ATPase homolog 1 (AHSA1) OTC7AFHT AHSA1_HUMAN Gene/Protein Processing [5]
Alanine--tRNA ligase, cytoplasmic (AARS1) OTW8D813 SYAC_HUMAN Gene/Protein Processing [5]
Aldo-keto reductase family 1 member C1 (AKR1C1) OTQKR4CM AK1C1_HUMAN Gene/Protein Processing [5]
ATP-dependent RNA helicase DDX55 (DDX55) OTH8ZBPA DDX55_HUMAN Gene/Protein Processing [5]
B-cell lymphoma 6 protein (BCL6) OTQAWWO1 BCL6_HUMAN Gene/Protein Processing [5]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Gene/Protein Processing [6]
Cbp/p300-interacting transactivator 2 (CITED2) OT812TV7 CITE2_HUMAN Gene/Protein Processing [5]
CCR4-NOT transcription complex subunit 2 (CNOT2) OT98OJ42 CNOT2_HUMAN Gene/Protein Processing [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Calcium stearate E00244 15324 lubricant
Magnesium stearate E00208 11177 lubricant
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Sodium phenylbutyrate 500 mg tablet 500 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 ClinicalTrials.gov (NCT00533559) Mechanism of Fatty Acid-induced Impairment of Glucose-simulated Insulin Secretion - Effect of Buphenyl. U.S. National Institutes of Health.
2 Sodium phenylbutyrate FDA Label
3 Histone Deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases. Curr Drug Targets. 2010 Nov;11(11):1430-8.
4 Polo-like kinase inhibitor Ro5203280 has potent antitumor activity in nasopharyngeal carcinoma.Mol Cancer Ther. 2013 Aug;12(8):1393-401.
5 Gene expression profile analysis of 4-phenylbutyrate treatment of IB3-1 bronchial epithelial cell line demonstrates a major influence on heat-shock proteins. Physiol Genomics. 2004 Jan 15;16(2):204-11.
6 Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis. PLoS One. 2018 Nov 27;13(11):e0207915. doi: 10.1371/journal.pone.0207915. eCollection 2018.